7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Osteoarthritis (OA) is a physically and emotionally debilitating disease that predominantly affects the aging adult population. Current pharmacologic treatment options primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated side effects, analgesic limitations, especially in the elderly, and the need for around-the-clock analgesia have led physicians to search for alternative analgesics. Opioids have shown effectiveness at mitigating both chronic cancer and noncancer pain, and their ability to be placed into controlled release (CR) formulations suggests that they may prove efficacious for OA patients. One formulation, oxycodone CR, has shown effectiveness in cancer pain patients and in some trials of noncancer low back pain. In this review, the objective was to synthesize the reported findings by researchers in this field and present an up-to-date look at the efficacy, safety, and tolerability of oxycodone CR in OA patients. Public literature databases were searched using specific keywords (eg, oxycodone CR) for studies assessing the efficacy and safety profile of oxycodone CR and its use in patients with OA. A total of eleven articles that matched the criteria were identified, which included three placebo-controlled trials, six comparative trials, one pharmacokinetic study in the elderly, and one long-term safety trial. Analysis of the studies revealed that oxycodone CR is reasonably efficacious, safe, and tolerable when used to manage moderate to severe chronic OA pain, with similar side effects to that of other opioids.

          Related collections

          Author and article information

          Journal
          J Pain Res
          J Pain Res
          Journal of Pain Research
          Dove Medical Press
          1178-7090
          2012
          23 April 2012
          : 5
          : 77-87
          Affiliations
          [1 ]NEMA Research Inc, Naples, FL
          [2 ]Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA
          [3 ]Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA
          [4 ]Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
          [5 ]Department of Anesthesiology, Georgetown University School of Medicine, Washington, DC, USA
          Author notes
          Correspondence: Robert Taylor Jr, NEMA Research Inc, 840 111th Avenue, North, Suite 9, Naples, FL 34108, USA, Tel +1 239 597 3662, Email robert.taylor.phd@ 123456gmail.com
          Article
          jpr-5-077
          10.2147/JPR.S21965
          3346069
          22570559
          © 2012 Taylor Jr et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Comments

          Comment on this article